This is not up-ramping, but if BOT only secures 1% of the patients that are already in a dermatologist’s office seeking help with their hyperhidrosis (1% of the existing 3.7m people seeking help), that's 37,000 patients who'll spend +$500/mnth on Sofdra. That's annual sales of more than $200m! And that's based on ONLY 1% of existing market!
Ann: Euroz Hartleys Healthcare Forum Presentation, page-11
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $689.3M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 37.5¢ | $1.784M | 4.691M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 248028 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 356327 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |